HeraMED (ASX:HMD) - CEO, David Groberman
CEO, David Groberman
Source: TechInvest Magazine
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Pregnancy technology company HeraMED (HMD) has signed a commercial agreement with Joondalup Health Campus (JHC)
  • Under the agreement, JHC will conduct a paid pilot of the company’s HeraCARE solution, involving 100 expectant mothers
  • Once the pilot is completed, HeraMED and JHC plan to enter into a comprehensive collaboration agreement
  • Under that agreement, the companies will deploy the HeraCARE platform as a standard service for all pregnant mothers at JHC
  • HeraMED is up four per cent and trading at 13 cents per share

Pregnancy technology company HeraMED (HMD) has signed a commercial agreement with Joondalup Health Campus (JHC).

Under the agreement, JHC will conduct a paid pilot of HeraMED’s HeraCARE solution, involving 100 expectant mothers. The pilot will allow these women to test the company’s comprehensive digital maternity care platform, which includes the HeraBEAT device.

The HeraBEAT device is a foetal and maternal heart rate monitor that can be used at home by the mother, allowing it to be used during remote telehealth consultations. JHC previously conducted a clinical trial of the HeraBEAT device, which produced excellent results in accuracy last year.

The device was able to detect the foetal heart rate 100 per cent of the time when used by clinicians and was also able to detect it 100 per cent of the time when used by expectant mothers without professional assistance.

HeraMED’s CEO, David Groberman, expressed the company’s delight at reaching this agreement with JHC.

“Representing the first agreement for the full-blown HeraCARE platform, on a Technology as a Service basis, it is in line with our commercialisation strategy and is expected to underpin further awareness of our technology amongst global healthcare providers,” he said.

“It is particularly pleasing that JHC have adopted HeraMED’s innovative technology, as it forms part of their strategic plan to become market leaders in adopting innovative care models based on digital health, home-based remote monitoring,” he added.

JHC will pay each user of the HeraCARE platform $50 a month during the pilot process. Once the pilot is completed, HeraMED and JHC intend to enter into a comprehensive follow-up collaboration agreement.

Under the follow-up agreement, the companies intend to fully deploy the HeraCARE platform as a standard service, available to all expectant mothers under JHC’s care. 

HeraMED is up four per cent, trading at 13 cents per share at 10:16 am AEST.

HMD by the numbers
More From The Market Online
Saccharomyces cerevisiae yeast, 3D illustration.

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Biotech company Tissue Repair Ltd (ASX:TRP) has seen its share price rise more than 30% on news it had gained TGA (Therapeutic
The Market Online Video

Little Green Pharma (ASX:LGP) reports revenue increase in Q4 FY24

This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts.
Illustration representing big data technology.

Opyl forms JV with UK and US consortium to bring products to the world

Medical technology and AI company Opyl Ltd is set to form a joint venture with UK…
Ai gen brain scan

EMVision Medical successfully fabs first prototype of First Responder brain scan device – portable enough for a backpack

EMVision Medical Devices (ASX:EMV) has announced its successful fabrication of a portable on-the-spot brain scanning device.